Neola Medical AB Net Assets
Neola Medical AB net assets. Based on the latest financial reports, Neola Medical AB (NEOLA) has net assets worth Skr97.59 Million SEK (≈ $10.50 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr104.44 Million ≈ $11.24 Million USD) and total liabilities (Skr6.86 Million ≈ $737.82K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NEOLA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr97.59 Million |
| % of Total Assets | 93.44% |
| Annual Growth Rate | 28.18% |
| 5-Year Change | 86.55% |
| 10-Year Change | N/A |
| Growth Volatility | 47.4 |
Net Assets of Neola Medical AB (2018–2025)
Net assets of Neola Medical AB from 2018 to 2025. This chart illustrates how Neola Medical AB's net assets have evolved over time, based on quarterly financial data. See NEOLA net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Neola Medical AB (2018–2025)
The table below shows the annual net assets of Neola Medical AB from 2018 to 2025. For live market cap and overall valuation, see market value of Neola Medical AB.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr75.80 Million ≈ $8.16 Million |
+9.92% |
| 2024-12-31 | Skr68.96 Million ≈ $7.42 Million |
-12.74% |
| 2023-12-31 | Skr79.03 Million ≈ $8.50 Million |
+17.10% |
| 2022-12-31 | Skr67.48 Million ≈ $7.26 Million |
+66.08% |
| 2021-12-31 | Skr40.63 Million ≈ $4.37 Million |
+72.57% |
| 2020-12-31 | Skr23.55 Million ≈ $2.53 Million |
+119.59% |
| 2019-12-31 | Skr10.72 Million ≈ $1.15 Million |
-19.55% |
| 2018-12-31 | Skr13.33 Million ≈ $1.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Neola Medical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1338.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Neola Medical AB Net Assets Breakdown (December 2025)
Neola Medical AB net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr5.57 Million | 7.35% |
| Other Comprehensive Income | Skr53.68 Million | 70.82% |
| Other Components | Skr116.38 Million | 153.53% |
| Total Equity | Skr75.80 Million | 100.00% |
Neola Medical AB Competitors by Market Cap
The table below lists competitors of Neola Medical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AHT Syngas Technology NV
F:3SQ1
|
$4.37 Million |
|
CPPGroup Plc
F:4CV1
|
$4.37 Million |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
$4.37 Million |
|
NanoVibronix Inc
NASDAQ:NAOV
|
$4.37 Million |
|
IDOX plc
LSE:IDOX
|
$4.36 Million |
|
One SA
WAR:FMG
|
$4.36 Million |
|
SINTEZA S.A.
RO:STZ
|
$4.36 Million |
|
CCSC Technology International Holdings Limited Ordinary Shares
NASDAQ:CCTG
|
$4.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neola Medical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 68,963,000 to 75,803,000, a change of 6,840,000 (9.9%).
- Net loss of 11,022,000 reduced equity.
- New share issuances of 19,500,000 increased equity.
- Other comprehensive income increased equity by 8,284,000.
- Other factors decreased equity by 9,922,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-11.02 Million | -14.54% |
| Share Issuances | Skr19.50 Million | +25.72% |
| Other Comprehensive Income | Skr8.28 Million | +10.93% |
| Other Changes | Skr-9.92 Million | -13.09% |
| Total Change | Skr- | 9.92% |
Book Value vs Market Value Analysis
This analysis compares Neola Medical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.53x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.69x to 0.53x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Skr0.76 | Skr0.52 | x |
| 2019-12-31 | Skr0.61 | Skr0.52 | x |
| 2020-12-31 | Skr2.47 | Skr0.52 | x |
| 2021-12-31 | Skr2.23 | Skr0.52 | x |
| 2022-12-31 | Skr2.59 | Skr0.52 | x |
| 2023-12-31 | Skr1.42 | Skr0.52 | x |
| 2024-12-31 | Skr0.98 | Skr0.52 | x |
| 2025-12-31 | Skr0.99 | Skr0.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neola Medical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-14.54%) is above the historical average (-16.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -5.71% | -132.35% | 0.04x | 1.05x | Skr-2.09 Million |
| 2019 | -24.30% | -16287.50% | 0.00x | 1.14x | Skr-3.68 Million |
| 2020 | -28.53% | -21667.74% | 0.00x | 1.10x | Skr-9.07 Million |
| 2021 | -16.37% | -1064.48% | 0.01x | 1.08x | Skr-10.72 Million |
| 2022 | -15.34% | 0.00% | 0.00x | 1.12x | Skr-17.10 Million |
| 2023 | -11.40% | 0.00% | 0.00x | 1.09x | Skr-16.91 Million |
| 2024 | -14.59% | 0.00% | 0.00x | 1.07x | Skr-16.96 Million |
| 2025 | -14.54% | 0.00% | 0.00x | 1.04x | Skr-18.60 Million |
Industry Comparison
This section compares Neola Medical AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $471,003,634
- Average return on equity (ROE) among peers: -36.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neola Medical AB (NEOLA) | Skr97.59 Million | -5.71% | 0.07x | $4.36 Million |
| Acarix A/S (ACARIX) | $75.70 Million | -87.44% | 0.07x | $23.63 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $13.21 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $417.44 Million | -6.35% | 0.62x | $53.79 Million |
| BICO Group AB (BICO) | $3.01 Billion | -0.18% | 0.82x | $174.69 Million |
| Boule Diagnostics AB (BOUL) | $269.60 Million | -82.83% | 1.19x | $3.55 Million |
| CellaVision AB (CEVI) | $815.73 Million | 17.25% | 0.24x | $490.26 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $10.83 Million | -64.40% | 0.20x | $9.27 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $35.05 Million | -30.59% | 0.38x | $82.28 Million |
| Duearity AB (DEAR) | $3.79 Million | -34.93% | 0.15x | $331.97K |
About Neola Medical AB
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume chan… Read more